"You can have the fanciest ideas and molecules, but if you can't get them into the cell, they are of no use.”
- Matthew Porteus, co-founder, crispr therapeutics
LIGANDAL AIMS TO FREE HUMANITY FROM COMPLEX DISEASES
THE PROBLEMThere are limited cell-specific delivery systems for gene editing and genetic engineering tools. Despite the advancement of technologies such as CRISPR, gene delivery remains a major limitation.
|
THE SOLUTIONLigandal is developing a comprehensive, cell-specific nanomedicine platform to unlock the human genome to tackle multiple complex diseases and deliver globally accessible personalized medicine.
|
GETTING THERELigandal will take a calculated, programmatic and market-driven approach to enabling broad industry adoption of its delivery technologies in key cell types and indications.
|
